Geron (GERN) Cash from Financing Activities (2010 - 2026)
Geron's (GERN) quarterly Cash from Financing Activities came in at $2.4 million in Q1 2026, up 847.27% year-on-year from $256000.0 in Q1 2025, and up 541.53% quarter-over-quarter from $378000.0 in Q4 2025.
Geron (GERN) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Geron has disclosed Cash from Financing Activities across 17 years of filings, most recently posting $2.4 million for Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at $2.4 million, up 847.27% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.4 million (down 97.63% YoY), and the FY2025 annual result was $2.3 million, down 99.32% from the prior year.
- Cash from Financing Activities came in at $2.4 million for Q1 2026 at Geron, up from $378000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $281.0 million in Q1 2023 to a low of $256000.0 in Q1 2025.
- The 5-year median for Cash from Financing Activities is $11.9 million (2022), against an average of $47.9 million.
- Across the five-year window, Cash from Financing Activities sank 99.83% in 2025 and surged 847.27% in 2026, its largest moves.
- Geron's Cash from Financing Activities stood at $11.9 million in 2022, then jumped by 179.12% to $33.3 million in 2023, then soared by 399.29% to $166.2 million in 2024, then tumbled by 99.77% to $378000.0 in 2025, then surged by 541.53% to $2.4 million in 2026.
- The last three Cash from Financing Activities figures came in at $2.4 million (Q1 2026), $378000.0 (Q4 2025), and $542000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 53,000.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 85,464.43 |
| 10 | Geron | 729,618.77 | 729,618.77 | - | 2.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.43 Mn |
| Mar 31, 2026 | 2.43 Mn |
| Dec 31, 2025 | 378,000.00 |
| Dec 31, 2025 | 378,000.00 |
| Sep 30, 2025 | 542,000.00 |
| Sep 30, 2025 | 542,000.00 |
| Jun 30, 2025 | 1.09 Mn |
| Jun 30, 2025 | 1.09 Mn |
| Mar 31, 2025 | 256,000.00 |
| Mar 31, 2025 | 256,000.00 |
| Dec 31, 2024 | 166.16 Mn |
| Dec 31, 2024 | 166.16 Mn |
| Sep 30, 2024 | 3.58 Mn |
| Sep 30, 2024 | 3.58 Mn |
| Jun 30, 2024 | 16.83 Mn |
| Jun 30, 2024 | 16.83 Mn |
| Mar 31, 2024 | 147.80 Mn |
| Mar 31, 2024 | 147.80 Mn |
| Dec 31, 2023 | 33.28 Mn |
| Dec 31, 2023 | 33.28 Mn |